Key result
Benazepril plus amlodipine reduced the primary composite cardiovascular endpoint compared to benazepril plus hydrochlorothiazide (9.6% vs 11.8%; HR 0.8; 95% CI 0.72-0.9; P<0.001).
Why the study?
Does the combination of benazepril and amlodipine reduce cardiovascular events compared to benazepril and hydrochlorothiazide in high-risk patients with hypertension?
RCT (n=11,506)
Double-blind
randomized
Yes
Does the combination of benazepril and amlodipine reduce cardiovascular events compared to benazepril and hydrochlorothiazide in high-risk patients with hypertension?
Hazard Ratio: 0.8 (95% CI 0.72–0.9)
Absolute Event Rate: 9.6% vs 11.8%
Absolute Risk Reduction: 2.2%
p-value: p=<.001
No takes yet. Share an insight, caveat, or question.
In high-risk hypertensive patients, combination therapy with an ACE inhibitor and amlodipine significantly reduced cardiovascular events compared to an ACE inhibitor and hydrochlorothiazide.
Cohen et al. (2009) conducted an RCT in Hypertension (n=11,506). Benazepril plus amlodipine vs. Benazepril plus hydrochlorothiazide was evaluated on Composite of death from CV causes, nonfatal myocardial infarction and nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization (HR 0.8, 95% CI 0.72-0.9, p=<.001). Benazepril plus amlodipine reduced the primary composite cardiovascular endpoint compared to benazepril plus hydrochlorothiazide (9.6% vs 11.8%; HR 0.8; 95% CI 0.72-0.9; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: